-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31

Benzinga·07/21/2026 12:45:25
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.